The clinical significance of negative flow cytometry immunophenotypic results in a morphologically scored positive bone marrow in patients following treatment for acute myeloid leukemia

American Journal of Hematology
Juan OuyangSa A Wang

Abstract

In a patient with acute myeloid leukemia (AML) following therapy, finding ≥5% bone marrow (BM) blasts is highly concerning for residual/relapsed disease. Over an 18-month period, we performed multicolor flow cytometry immunophenotyping (MFC) for AML minimal residual disease on >4,000 BM samples, and identified 41 patients who had ≥5% myeloblasts by morphology but negative by MFC. At the time of a negative MFC study, an abnormal cytogenetic study converted to negative in 14 patients and remained positive at a low level (2.5-9.5%) by fluorescence in situ hybridization in 3 (14%), of the latter, abnormalities subsequently disappeared in the repeated BM in 2 patients. Positive pretreatment mutations, including FLT3, NPM1, IDH1, CEBPA, became negative in all 10 patients tested. Of the seven patients with favorable cytogenetics, PML/RARA, CBFB-MYH11 or RUNX1-RUNX1T1 fusion transcripts were detected at various levels in six patients but all patients remained in complete remission. With no additional chemotherapy given, 39 patients had BM repeated (median 2 weeks, range <1-21), and all cases showed <5% BM blasts and a continuously negative MFC. In the end of follow-up (median 10 months, range 1-22), 13 patients experienced relapse, 12/...Continue Reading

References

Sep 30, 1999·The New England Journal of Medicine·B LöwenbergA Burnett
Feb 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F MorschhauserC Preudhomme
Jul 26, 2002·British Journal of Haematology·Bert A van der ReijdenJoop H Jansen
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Nov 9, 2011·Clinical Lymphoma, Myeloma & Leukemia·Jeffrey L Jorgensen, Su S Chen
Mar 16, 2012·The New England Journal of Medicine·Matthew J WalterTimothy A Graubert
Jul 24, 2012·Cell·John S WelchRichard K Wilson
Aug 11, 2012·Journal of the National Comprehensive Cancer Network : JNCCN·Farhad Ravandi, Jeffrey L Jorgensen
Aug 25, 2012·Blood·Elisabeth Paietta
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana
Feb 6, 2013·Current Opinion in Hematology·Elaine Coustan-Smith, Dario Campana
Mar 26, 2013·American Journal of Hematology·Elihu H Estey
Jun 27, 2013·Nature Reviews. Clinical Oncology·Christopher S Hourigan, Judith E Karp
Jul 3, 2013·The Journal of Molecular Diagnostics : JMD·Rajesh R SinghRajyalakshmi Luthra
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Monique TerwijnGerrit J Schuurhuis
Sep 26, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanAlan K Burnett
Oct 24, 2013·Cytometry. Part B, Clinical Cytometry·W ZeijlemakerG J Schuurhuis
Nov 19, 2013·Cytometry. Part B, Clinical Cytometry·Michael R Loken
Nov 6, 2014·British Journal of Haematology·Gro G PløenAnni Aggerholm

❮ Previous
Next ❯

Citations

Jun 27, 2015·Seminars in Hematology·Peter HoklandChristopher S Hourigan
Aug 8, 2015·American Journal of Hematology·Neil CameSurender Juneja
Mar 31, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sylvie D FreemanNigel H Russell
Feb 14, 2019·Annals of Hematology·Wei XieGuilin Tang
Dec 7, 2019·Hematology·Sylvie D Freeman, Christopher S Hourigan
Jul 11, 2018·World Journal of Stem Cells·Cristina MambetCarmen Cristina Diaconu
Feb 9, 2020·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Wei XieGuilin Tang
Jan 18, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lina HanMarina Konopleva

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.